OptiBiotix Health PLC (AIM:OPTI, OTCQB:OPTBF), the AIM-listed life sciences company developing gut microbiome products and healthy sugar substitutes, saw its shares jump 13.5% to 5.68p after announcing plans to demonstrate its SweetBiotix products to shareholders at a London event in June.
The company reported a breakthrough in the manufacture of SweetBiotix in November 2025, achieving higher yields of a purer, more concentrated and better-tasting product with lower ingredient and production costs.
OptiBiotix said it is now in a position to let investors sample the product first-hand and is asking shareholders and prospective investors to register their interest to help determine venue size.
The event will include an overview of the commercial progress of OptiBiotix's first and second-generation products and their route to market alongside the sampling session.
SweetBiotix is a range of sweet fibres designed as healthy sugar substitutes.
OptiBiotix's broader product portfolio is focused on reducing hunger and food cravings and enhancing the gut microbiome.